2020
DOI: 10.1007/s00044-020-02502-x
|View full text |Cite
|
Sign up to set email alerts
|

A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery

Abstract: mTOR/MEK bifunctional inhibitors have the potential to surmount the drug resistance aroused from cross talk between PI3K/Akt/mTOR (PAM) and Ras/MEK/ERK pathways. Herein, we report the discovery of a conjugated dual-targeted molecule, compound 13, as the prototype mTOR/MEK bifunctional inhibitor. It exhibited moderately high inhibitory activity against mTOR and MEK1 with IC 50 values of 0.19 μM and 0.98 μM, respectively. In particular, it displayed attractive antiproliferative activity against both A549 (GI 50 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 20 publications
0
2
0
Order By: Relevance
“…Therefore, to identify potential MEK1 inhibitors with good efficacy, molecular docking, long‐term molecular dynamics (MD) simulations, and molecular mechanics Poisson–Boltzmann surface area (MM‐PBSA) studies were implemented. Previous studies as well as the patents have claimed several quinoline derivatives as a prosperous scaffold for cancer and a noncompetitive inhibitor of MEK1 18–23 . In this study, we have selected 37 in‐house quinoline derivatives to discover allosteric inhibitors of MEK1 in comparison with four reference molecules (three identified inhibitors and one cocrystal) 24 …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Therefore, to identify potential MEK1 inhibitors with good efficacy, molecular docking, long‐term molecular dynamics (MD) simulations, and molecular mechanics Poisson–Boltzmann surface area (MM‐PBSA) studies were implemented. Previous studies as well as the patents have claimed several quinoline derivatives as a prosperous scaffold for cancer and a noncompetitive inhibitor of MEK1 18–23 . In this study, we have selected 37 in‐house quinoline derivatives to discover allosteric inhibitors of MEK1 in comparison with four reference molecules (three identified inhibitors and one cocrystal) 24 …”
Section: Introductionmentioning
confidence: 99%
“…Previous studies as well as the patents have claimed several quinoline derivatives as a prosperous scaffold for cancer and a noncompetitive inhibitor of MEK1. [18][19][20][21][22][23] In this study, we have selected 37 in-house quinoline derivatives to discover allosteric inhibitors of MEK1 in comparison with four reference molecules (three identified inhibitors and one cocrystal). 24 2 | COMPUTATIONAL METHODOLOGY…”
mentioning
confidence: 99%